secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001655759-25-000057
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas and Pfizer report Phase 3 VERITAC-2 hit: vepdegestrant improves PFS in ESR1m breast cancer; ITT miss
--------------------------------------------------------------------------------

- Vepdegestrant met primary endpoint in ESR1m population: statistically significant PFS improvement, exceeded target HR of 0.60.
- ITT population did not achieve statistical significance for PFS.
- Overall survival not mature (<25% of required events); trial continuing.
- Safety profile consistent with prior studies; detailed results to be submitted to medical meeting and regulators.
- First PROTAC degrader to show Phase 3 clinical benefit; Fast Track designation previously granted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575925000057/0001655759-25-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575925000057/arvn-20250311.htm
  HTML page:      https://secwatch.observer/filing/0001655759-25-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer